PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024 08:00 ET
|
PMV Pharmaceuticals, Inc.
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors ...
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
May 09, 2024 08:00 ET
|
Apnimed, Inc.
Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
May 09, 2024 08:00 ET
|
Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET
|
VYNE Therapeutics Inc.
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately 160 subjects with either active or stable...
Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation
May 09, 2024 08:00 ET
|
Volta Medical
Published in the EP Europace Journal, the consensus statement highlights Volta’s AI Companion and the TAILORED-AF clinical trial. MARSEILLE, France, May 09, 2024 (GLOBE NEWSWIRE) -- Volta Medical,...
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
May 09, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
May 09, 2024 08:00 ET
|
Cerevance
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the...
Shoals Technologies Group Expands Leadership Team with Key Appointments in International Business and Investor Relations
May 09, 2024 08:00 ET
|
Shoals Technologies Group
PORTLAND, Tenn., May 09, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc., a leading provider of electrical balance of systems (“EBOS”) solutions for solar, battery storage, and electric...
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 08:00 ET
|
Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
Rush Street Interactive to Participate at the Needham Technology, Media, & Consumer Conference
May 09, 2024 08:00 ET
|
Rush Street Interactive, Inc.
CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) -- Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States and the rest of the Americas,...